ImmunityBio (NASDAQ:IBRX) Announces Quarterly Earnings Results, Beats Estimates By $0.02 EPS

ImmunityBio (NASDAQ:IBRX) released its earnings results on Monday. The company reported ($0.06) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.02, FiscalAI reports. The firm had revenue of $38.29 million for the quarter.

ImmunityBio Stock Performance

ImmunityBio stock opened at $8.70 on Monday. ImmunityBio has a 52 week low of $1.83 and a 52 week high of $9.25. The firm has a market capitalization of $8.57 billion, a price-to-earnings ratio of -21.22 and a beta of 0.14. The company has a 50 day moving average price of $4.48 and a 200 day moving average price of $3.12.

Key Headlines Impacting ImmunityBio

Here are the key news stories impacting ImmunityBio this week:

• Positive Sentiment: European conditional approval and EU commercialization push — the European Commission granted conditional marketing authorization for ANKTIVA® in combination with BCG for BCG‑unresponsive NMIBC CIS, and ImmunityBio is opening an Irish subsidiary and signing distribution deals (Accord) to support the EU launch, which meaningfully expands addressable market and revenue runway. ImmunityBio Expands Access to ANKTIVA® in EU (BusinessWire)
• Positive Sentiment: Regional commercial expansion — ImmunityBio struck a partnership with Biopharma and Cigalah Healthcare to launch ANKTIVA® in Saudi Arabia and the broader MENA region, giving the drug local distribution partners and accelerating market entry in a sizeable oncology market. ImmunityBio Partners to Launch ANKTIVA in Saudi Arabia (BusinessWire)
• Positive Sentiment: Technical momentum — the stock is showing strong technicals (reported “golden cross” and trading well above the 200‑day average), reinforcing momentum traders and institutional interest. ImmunityBio Holds Golden Cross (Benzinga)
• Neutral Sentiment: Chairman commentary and publicity — public comments linking diplomatic efforts to commercial success have generated headlines and may sustain retail interest, but they are narrative-driven rather than new financial data. Chairman Comments on Diplomacy (MSN)
• Neutral Sentiment: Corporate finance/clinical updates referenced in coverage — some articles note follow‑up clinical programs and past convertible‑note activity; these are worth monitoring for dilution or R&D progress but contain no immediate financial details. Clinical/Convertible Note Context (MSN)
• Negative Sentiment: Investor litigation investigation — Pomerantz LLP announced an investigation into ImmunityBio on behalf of investors, which introduces legal and reputational risk that could pressure the stock if it leads to claims or disclosures. Pomerantz Investigates (PR Newswire)

Insiders Place Their Bets

In related news, Director Christobel Selecky sold 25,000 shares of the company’s stock in a transaction on Tuesday, January 20th. The stock was sold at an average price of $7.51, for a total transaction of $187,750.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Barry J. Simon sold 151,967 shares of the stock in a transaction dated Tuesday, January 20th. The stock was sold at an average price of $7.20, for a total value of $1,094,162.40. Following the completion of the sale, the director directly owned 3,091,604 shares of the company’s stock, valued at approximately $22,259,548.80. This represents a 4.69% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 226,967 shares of company stock valued at $1,531,912 in the last 90 days. Corporate insiders own 69.48% of the company’s stock.

Institutional Trading of ImmunityBio

A number of hedge funds have recently made changes to their positions in IBRX. Mariner LLC boosted its holdings in shares of ImmunityBio by 10.5% during the fourth quarter. Mariner LLC now owns 17,814 shares of the company’s stock worth $35,000 after purchasing an additional 1,689 shares during the period. Commonwealth Equity Services LLC boosted its stake in shares of ImmunityBio by 4.5% during the 4th quarter. Commonwealth Equity Services LLC now owns 75,776 shares of the company’s stock valued at $150,000 after buying an additional 3,280 shares during the period. Engineers Gate Manager LP grew its holdings in shares of ImmunityBio by 15.3% during the 4th quarter. Engineers Gate Manager LP now owns 26,968 shares of the company’s stock valued at $53,000 after acquiring an additional 3,578 shares in the last quarter. Creative Planning increased its stake in shares of ImmunityBio by 9.2% in the second quarter. Creative Planning now owns 62,028 shares of the company’s stock worth $164,000 after acquiring an additional 5,231 shares during the last quarter. Finally, Xponance LLC increased its stake in shares of ImmunityBio by 29.4% in the fourth quarter. Xponance LLC now owns 23,168 shares of the company’s stock worth $46,000 after acquiring an additional 5,270 shares during the last quarter. 8.58% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on IBRX shares. HC Wainwright raised their price objective on shares of ImmunityBio from $8.00 to $10.00 and gave the company a “buy” rating in a research report on Monday, January 26th. Weiss Ratings restated a “sell (e+)” rating on shares of ImmunityBio in a report on Monday, December 29th. Jefferies Financial Group upped their price target on ImmunityBio from $8.00 to $9.00 and gave the company a “buy” rating in a report on Friday, December 12th. BTIG Research increased their price objective on ImmunityBio from $6.00 to $9.00 and gave the company a “buy” rating in a research report on Thursday, January 22nd. Finally, Piper Sandler lifted their target price on ImmunityBio from $5.00 to $7.00 and gave the stock an “overweight” rating in a report on Tuesday, January 20th. Five equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $11.80.

About ImmunityBio

ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.

Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.